MA27521A1 - Conjugues de polymeres avec antigenicite reduite, procedes de preparation et utilisations de ces conjugues - Google Patents

Conjugues de polymeres avec antigenicite reduite, procedes de preparation et utilisations de ces conjugues

Info

Publication number
MA27521A1
MA27521A1 MA28243A MA28243A MA27521A1 MA 27521 A1 MA27521 A1 MA 27521A1 MA 28243 A MA28243 A MA 28243A MA 28243 A MA28243 A MA 28243A MA 27521 A1 MA27521 A1 MA 27521A1
Authority
MA
Morocco
Prior art keywords
conjugates
methods
preparation
compositions
polymer conjugates
Prior art date
Application number
MA28243A
Other languages
English (en)
Inventor
Alexa L Martinez
Merry R Sherman
Mark G P Saifer
L David Williams
Original Assignee
Mountain View Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals filed Critical Mountain View Pharmaceuticals
Publication of MA27521A1 publication Critical patent/MA27521A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Cette invention sa rapporte à des procédés servant à la préparation de conjugués de divers composants bioactifs, notamment des protéines, avec des polymères hydrosolubles (par exemple du poly(éthylène glycol) et des dérivés de celui-ci), ces conjugués ayant une antigénicité et une immunogénicité réduites par rapport à des conjugués similaires préparés au moyen de poly(éthylène glycol) contenant un méthoxyle ou un autre groupe alkoxyle. Cette invention concerne également des conjugués préparés par ces procédés, des compositions comprenant ces conjugués, des kits contenant ces conjugués ou ces compositions et des procédés d'utilisation de ces conjugués et de ces compositions dans des protocoles diagnostiques et thérapeutiques.
MA28243A 2002-09-30 2005-04-29 Conjugues de polymeres avec antigenicite reduite, procedes de preparation et utilisations de ces conjugues MA27521A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41442402P 2002-09-30 2002-09-30
US10/317,092 US20040062748A1 (en) 2002-09-30 2002-12-12 Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Publications (1)

Publication Number Publication Date
MA27521A1 true MA27521A1 (fr) 2005-09-01

Family

ID=32033300

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28243A MA27521A1 (fr) 2002-09-30 2005-04-29 Conjugues de polymeres avec antigenicite reduite, procedes de preparation et utilisations de ces conjugues

Country Status (26)

Country Link
US (1) US20040062748A1 (fr)
EP (2) EP1572728B1 (fr)
JP (2) JP5366352B2 (fr)
KR (1) KR101022577B1 (fr)
CN (2) CN1997661B (fr)
AU (1) AU2003275176B8 (fr)
BR (1) BRPI0314831B8 (fr)
CA (2) CA2836959C (fr)
CR (1) CR7776A (fr)
DK (1) DK1572728T3 (fr)
EA (1) EA009122B1 (fr)
EC (1) ECSP055717A (fr)
ES (1) ES2504165T3 (fr)
GE (1) GEP20074016B (fr)
HK (1) HK1083190A1 (fr)
HR (1) HRP20050353B1 (fr)
IL (1) IL167723A (fr)
IS (1) IS2944B (fr)
MA (1) MA27521A1 (fr)
MX (1) MXPA05003394A (fr)
NO (1) NO20052089L (fr)
NZ (1) NZ539133A (fr)
PT (1) PT1572728E (fr)
RS (1) RS20050263A (fr)
TW (1) TWI362942B (fr)
WO (1) WO2004030617A2 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
EP2311432B1 (fr) * 2002-06-07 2014-12-24 Dyax Corporation Polypeptide contenant domaine de Kunitz modifiés et leur utilisation pour la réduction de l'ischémie ou de l'apparition d'une réponse inflammatoire systémique associée à une procédure chirurgicale
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
GEP20084487B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (fr) 2005-05-25 2006-11-30 Neose Technologies, Inc. Facteur ix glycopegyle
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
CN1823088B (zh) 2003-05-12 2011-04-13 阿费麦克斯公司 结合红细胞生成素受体的新肽
EP2204193A3 (fr) 2003-05-12 2010-08-18 Affymax, Inc. Groupe espaceur pour composés à base de peptides de poly(éthylèneglycol) modifiés
WO2005012484A2 (fr) 2003-07-25 2005-02-10 Neose Technologies, Inc. Conjugues anticorps-toxines
JP4739207B2 (ja) * 2003-08-29 2011-08-03 ダイアックス コーポレーション ポリペグ化されたプロテアーゼインヒビター
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1765853B1 (fr) 2004-01-08 2015-10-28 ratiopharm GmbH O-glycosylation de peptides G-CSF
WO2006010143A2 (fr) 2004-07-13 2006-01-26 Neose Technologies, Inc. Remodelage de peg ramifie et glycosylation de peptide-1 semblable a glucagon [glp-1]
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP3061461A1 (fr) 2004-10-29 2016-08-31 ratiopharm GmbH Remodelage et glycopegylation du facteur de croissance des fibroblastes (fgf)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
WO2006121569A2 (fr) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions et methodes utilisees pour la preparation de mutants par glycosylation de l'hormone de croissance humaine resistant a la protease
US7858080B2 (en) * 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (fr) 2005-11-03 2007-05-18 Neose Technologies, Inc. Purification de sucre de nucleotide en utilisant des membranes
CN101500614B (zh) * 2006-02-28 2011-08-10 雷迪实验室（欧洲）有限公司 制备聚乙二醇碳酸酯的方法
JPWO2007102562A1 (ja) * 2006-03-01 2009-07-23 学校法人慶應義塾 新規抗血栓薬
CA2653748A1 (fr) * 2006-05-02 2007-11-15 Allozyne, Inc. Polypeptides substitues par des acides amines non naturels
US20080096819A1 (en) * 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2101821B1 (fr) 2006-12-15 2014-08-13 Baxter International Inc. Conjugué du facteur viia et de l'acide (poly)sialique présentant une demi-vie in vivo prolongée
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
WO2008154639A2 (fr) 2007-06-12 2008-12-18 Neose Technologies, Inc. Procédé amélioré pour la production de sucres de nucléotide
CA2707840A1 (fr) * 2007-08-20 2009-02-26 Allozyne, Inc. Molecules substituees par des acides amines
EP2195010A4 (fr) * 2007-08-21 2012-03-14 Genzyme Corp Traitement par des inhibiteurs de la kallikréine
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
CA2744235A1 (fr) 2009-01-06 2010-07-15 Dyax Corp. Traitement de la mucosite par des inhibiteurs de kallikreine
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
MX2012001207A (es) 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2856055T3 (es) 2009-07-27 2021-09-27 Baxalta GmbH Glicopolisialilación de proteínas diferentes de las proteínas de coagulación de la sangre
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
EP2521568B1 (fr) 2010-01-06 2018-07-25 Dyax Corp. Protéines liant les kallicréines plasmatiques
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CA3065178C (fr) 2010-12-13 2022-02-01 Quiapeg Pharmaceuticals Ab Polymeres fonctionnalises
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
IL310186A (en) 2011-01-06 2024-03-01 Takeda Pharmaceuticals Co KALLIKREIN PLASMA BINDING PROTEINS
JP5949037B2 (ja) 2011-03-30 2016-07-06 日油株式会社 末端に複数の水酸基を有するポリオキシエチレン誘導体
WO2013186632A2 (fr) * 2012-06-12 2013-12-19 Quiapeg Ab Conjugués de molécules biologiquement actives à des polymères fonctionnalisés
EP2966083B1 (fr) * 2013-03-05 2019-06-05 Hanmi Pharm. Co., Ltd. Procédé de préparation amélioré pour la production à haut débit d'un conjugué polypeptidique physiologiquement actif
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
JP2017516869A (ja) * 2014-06-04 2017-06-22 ジム バイオサイエンシズ，インコーポレイテッド 皮膚の質を改善するための組成物及び方法
WO2016109400A2 (fr) 2014-12-31 2016-07-07 Lantheus Medical Imaging, Inc. Compositions de microsphères de gaz encapsulées dans des lipides et procédés associés
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
AU2017260532A1 (en) 2016-05-04 2018-11-22 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
WO2018163131A1 (fr) 2017-03-10 2018-09-13 Quiapeg Pharmaceuticals Ab Conjugués libérables
BR112021004689A2 (pt) 2018-09-12 2021-06-08 Quiapeg Pharmaceuticals Ab conjugados glp-1 liberáveis
CN110376369B (zh) * 2019-07-30 2022-02-15 重庆派金生物科技有限公司 一种抗聚乙二醇抗体的抗原区免疫原性分析方法
EP4052726A4 (fr) 2019-10-29 2023-12-20 National University Corporation Kumamoto University Composé mimétique de cd4 à activité anti-vih
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
GB1578348A (en) * 1976-08-17 1980-11-05 Pharmacia Ab Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4434228A (en) * 1982-04-20 1984-02-28 Genex Corporation Immobilization of biological materials in condensed polyalkyleneimine polymers
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IE64284B1 (en) 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
ZA933926B (en) * 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6180134B1 (en) * 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
WO1994027498A1 (fr) * 1993-05-20 1994-12-08 The Regents Of The University Of California Agent de contraste macromoleculaire s'utilisant en imagerie par resonance magnetique
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
AU7113594A (en) * 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
CA2174350A1 (fr) * 1993-10-20 1995-04-27 Richard B. Greenwald Substances taxoides substituees en position 2' et/ou 7'
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5711944A (en) 1993-11-10 1998-01-27 Enzon, Inc. Interferon polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
JP2001511162A (ja) * 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
CA2288994C (fr) * 1997-04-30 2011-07-05 Enzon, Inc. Polypeptides a chaine unique modifies par oxyde de polyalkylene
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6448369B1 (en) * 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6239262B1 (en) * 1998-01-07 2001-05-29 Rensselaer Polytechnic Institute Low molecular weight displacers for protein purification in hydrophobic interaction and reversed phase chromatographic systems
US5880225A (en) * 1998-02-18 1999-03-09 Arco Chemical Technology, L.P. Process for making polyetherester resins having high aromatic diester
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
BRPI9912974B8 (pt) 1998-08-06 2021-05-25 Univ Duke conjugados de peg-urato oxidase e seu uso
ES2404074T3 (es) 1998-08-06 2013-05-23 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso
CA2351739A1 (fr) 1998-08-28 2000-03-09 Gryphon Sciences Chaines polyamides de longueur precise, procede de fabrication et leur conjugues avec des proteines
CN1329082C (zh) * 1998-10-16 2007-08-01 拜奥根Idec马萨诸塞公司 干扰素－β－1a的聚合物缀合物及其使用
GB9822963D0 (en) 1998-10-20 1998-12-16 Agner Erik Improvements in or relating to chromatography
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
PT1455839E (pt) 1999-10-08 2013-04-24 Nektar Therapeutics Derivados de poli(etilenoglicol) heterobifuncionais e seus métodos de preparação
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6639493B2 (en) 2001-03-30 2003-10-28 Arizona State University Micro machined RF switches and methods of operating the same
DE60229958D1 (de) * 2001-06-28 2009-01-02 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
AU2003220917A1 (en) * 2002-03-29 2003-10-13 Daiichi Pharmaceutical Co., Ltd. Phospholipid derivative
US20040062748A1 (en) * 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof

Also Published As

Publication number Publication date
RS20050263A (en) 2007-08-03
ECSP055717A (es) 2005-08-11
JP5603823B2 (ja) 2014-10-08
NO20052089L (no) 2005-04-28
AU2003275176A1 (en) 2004-04-23
ES2504165T3 (es) 2014-10-08
AU2003275176B2 (en) 2008-12-18
CA2500389A1 (fr) 2004-04-15
KR20050083702A (ko) 2005-08-26
BR0314831A (pt) 2005-08-16
PT1572728E (pt) 2014-09-19
GEP20074016B (en) 2007-01-10
EA200500519A1 (ru) 2005-12-29
CA2500389C (fr) 2015-03-10
JP2006510601A (ja) 2006-03-30
IS7778A (is) 2005-03-30
CA2836959A1 (fr) 2004-04-15
EP2535347A1 (fr) 2012-12-19
IS2944B (is) 2016-04-15
JP5366352B2 (ja) 2013-12-11
CA2836959C (fr) 2017-06-06
BRPI0314831B1 (pt) 2021-01-19
MXPA05003394A (es) 2005-10-05
AU2003275176B8 (en) 2009-01-08
DK1572728T3 (da) 2014-09-22
HK1083190A1 (en) 2006-06-30
HRP20050353A2 (en) 2006-06-30
JP2011157379A (ja) 2011-08-18
TW200416035A (en) 2004-09-01
CN1997661B (zh) 2013-12-04
NZ539133A (en) 2008-03-28
CN1997661A (zh) 2007-07-11
KR101022577B1 (ko) 2011-03-16
WO2004030617A3 (fr) 2005-07-21
CR7776A (es) 2007-10-07
WO2004030617A2 (fr) 2004-04-15
EP1572728A2 (fr) 2005-09-14
TWI362942B (en) 2012-05-01
EP1572728A4 (fr) 2010-03-10
BRPI0314831B8 (pt) 2021-05-25
EP1572728B1 (fr) 2014-06-25
IL167723A (en) 2013-01-31
HRP20050353B1 (hr) 2013-07-31
US20040062748A1 (en) 2004-04-01
EA009122B1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
MA27521A1 (fr) Conjugues de polymeres avec antigenicite reduite, procedes de preparation et utilisations de ces conjugues
DK0946637T3 (da) Polymerfilm-sammensætning til kapsler
DK1261377T3 (da) Immunmodulatoriske formuleringer og fremgangsmåder til anvendelse af disse
GEP20063917B (en) Pulmonary administration of chemically modified insulin
MA27551A1 (fr) Composition immunogene
DE60323756D1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
EA200702575A1 (ru) Иммуногенная композиция
WO2006005058A3 (fr) Conjugues polymere-fraction facteur ix
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
BRPI0210335B8 (pt) copolímero de blocos, e, composição
BR0211926A (pt) agentes para realçar a resposta imune
GB2436996B (en) Rigid amines
DE602005025355D1 (de) Konjugate enthaltend gm-csf und ein polymer
AU2002252638A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
GB0123572D0 (en) Polymer compositions
AU2003250391A8 (en) Conjugates of biocompatible polymers with nuclide activation therapy reagents
NO20030495L (no) Peptider som presenteres av celler
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
WO2003035651A3 (fr) Derives de l'artemisinine, et leurs utilisations dans le traitement du paludisme
YU72802A (sh) Farmaceutske smeše koje sadrže oligosaharide, novi oligosaharidi i njihovo dobijanje
CA2373252A1 (fr) Peptides antiangiogeniques durables
DE60041198D1 (de) Antimikrobielle zusammensetzungen
WO2003000179A3 (fr) Conjugues de proteine « progenipoietin » chimiquement modifies
TNSN05095A1 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof